Company intelligence / Profile preview
QuadMedicine
Seongnam, Gyeonggi-do, South Koreaquadmedicine.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
QuadMedicine has demonstrated that its microneedle patches can deliver vaccines and allergens effectively into the skin with minimal pain. Preclinical studies show precise dosing and effective immunization in animal models. The company is developing multi-vaccine patches for use in low-resource settings with support from global health organizations. No late-stage or commercialized products are reported as of June 2025.
- Therapeutic areas
- ImmunologyInfectious Diseases
- Modalities
- Microneedle array patch (MAP)VaccineDNA vaccineSmall molecule (potential, based on drug delivery platform)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
International Vaccine Institute (IVI)LG Chem
Beyond the preview
Go deeper on QuadMedicine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QuadMedicine.